NCT03837899 2024-10-29Durvalumab and Tremelimumab for Pediatric MalignanciesAstraZenecaPhase 1/2 Active not recruiting50 enrolled 59 charts
NCT02775903 2023-02-28An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)CelgenePhase 2 Completed213 enrolled 35 charts